Conditions: Thrombocytopenia Related to Chronic Liver Disease
Keywords: Thrombocytopenia chronic liver disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 130
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Avatrombopag intervention 2: Avatrombopag intervention 3: Placebo
Intervention descriptions: intervention 1: Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days intervention 2: Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days intervention 3: Placebo or inactive substance once a day for up to 7 days

Protocol document: